Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma's Narrowed Patent Protection May Find Relief In Trade Secret Law

Executive Summary

A new law intended to better secure trade secrets may also help biopharmaceutical companies safeguard their intellectual property in situations where protection isn't available under the patenting process or the scope of a firm's patent was narrowed because of recent Supreme Court rulings.

You may also be interested in...



World-Top Scientist Busted For Stealing GSK Secrets

US prosecutors have laid out yet another case where very intelligent people made the stupid mistake of thinking they were too smart to get caught.

US Capitol Capsule: Time To Get Aggressive Against Trade Secret Bandits

With the theft of American companies' trade secrets increasingly on the rise – including those belonging to biopharmaceutical firms – lawmakers last week said more needs to be done to ensure there are stronger legal protections in place to secure that commercially valuable information.

US Capitol Capsule: Obama takes aim at trade secret thieves, counterfeiters

With the annual loss to the American economy from intellectual property (IP) theft at about $300 billion – plus millions of jobs lost – the Obama administration last week launched the second stage of its plan of attack against counterfeiters, patent infringers and cybercriminals that are stealing corporate trade and US government secrets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel